ScholarIQanswers from OpenAlex & ORCID
Charles G. Drake
ResearcherPublications, citations & collaboration network
Charles G. Drake is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Charles G. Drake have?
ScholarIQindexed works
Charles G. Drake has 1,156 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Charles G. Drake have?
ScholarIQcitation count
Charles G. Drake has 91,871 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Charles G. Drake?
ScholarIQh-index
Charles G. Drake has an h-index of 134 in OpenAlex.
What is the i10-index of Charles G. Drake?
ScholarIQi10-index
Charles G. Drake has an i10-index of 430 in OpenAlex.
What is the ORCID of Charles G. Drake?
ScholarIQorcid
The ORCID for Charles G. Drake is on the source record.
What is the OpenAlex record for Charles G. Drake?
ScholarIQopenalex
The OpenAlex for Charles G. Drake is on the source record.
What are the most-cited papers on Charles G. Drake?
ScholarIQmost cited works
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, Wen-Jen Hwu, Suzanne L. Topalian, Patrick Hwu, Charles G. Drake, Luis H. Camacho, John Kauh, Kunle Odunsi, Henry C. Pitot, Omid Hamid, Shailender Bhatia, Renato Martins, Keith D. Eaton, Shuming Chen, Theresa M. Salay, Suresh Alaparthy, Joseph F. Grosso, Alan J. Korman, Susan Parker, Shruti Agrawal, S. Goldberg, Drew M. Pardoll, Ashok Gupta, Jon M. Wigginton
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer, Charles G. Drake, Ira Wollner, John D. Powderly, Joel Picus, William H. Sharfman, Elizabeth Stankevich, Alice Pons, Theresa M. Salay, Tracee L. McMiller, Marta M. Gilson, Changyu Wang, Mark Selby, Janis M. Taube, Robert A. Anders, Lieping Chen, Alan J. Korman, Drew M. Pardoll, Israel Lowy, Suzanne L. Topalian
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng‐Ryong Woo, Meghan E. Turnis, Monica V. Goldberg, Jaishree Bankoti, Mark Selby, Christopher J. Nirschl, Matthew L. Bettini, David M. Gravano, Peter Vogel, Chih Long Liu, Stephanie Tangsombatvisit, Joseph F. Grosso, George J. Netto, Matthew P. Smeltzer, Alcides Chaux, Paul J. Utz, Creg J. Workman, Drew M. Pardoll, Alan J. Korman, Charles G. Drake, Dario A.A. Vignali
Prostate cancer
Gerhardt Attard, Chris Parker, Rosalind A. Eeles, Fritz H. Schröder, Scott A. Tomlins, Ian F. Tannock, Charles G. Drake, Johann S. de Bono